Process optimization of mRNA purification for vaccines and therapeutic applications

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

The success of mRNA vaccines in combating a global pandemic highlights the power of this technology not only to revolutionize prophylactic treatments for infectious diseases, but also to treat other diseases such as cancer. Critical to bringing these medicines to patients is an efficient, effective, and scalable downstream production process.

One of the molecular hallmarks of mRNA is its 3-prime poly-A tail, consisting of many consecutive adenylate bases. Leveraging fundamental A:T base complementarity, an affinity resin was developed to simplify affinity capture of in vitro transcribed mRNA.

This webinar will address the development, characterization, and optimization of an mRNA capture step using POROS Oligo(dT)25 resin. mRNA research techniques have developed over several decades, and associated traditional purification methods have proven challenging to scale. A newer affinity solution leveraging the rigid POROS backbone with its linear pressure-flow relationship enables a consistent purification platform, from process development through to clinical manufacturing.

• Considerations for selection of affinity capture step in the downstream purification of mRNA
• Performance data of the POROS Oligo(dt)25 affinity resin under various conditions and feeds
• Practical approaches via Design of Experiments (DoE) to optimize binding capacity and yield an effective capture step for mRNA vaccines and therapeutics
• Effective strategies to control cost of goods including resin cleaning and re-use conditions, and performance data

Chantelle Gaskin

Staff Scientist, Field Applications at Thermo Fisher Scientific

Chantelle Gaskin is a Field Applications Staff Scientist, specializing in protein and viral vector purification and downstream process development. She held leadership positions at Applied Genetic Technology Corporation and Brammer Bio, prior to joining the Thermo Fisher Scientific Bioproduction Division in 2020. With over 10 years of experience in gene therapy, Chantelle has accumulated comprehensive knowledge of standard industry practices and regulatory standards, applying this knowledge to advance development of therapies for a variety of indications including ocular, CNS and systemic disease.

Chantelle holds a Master’s degree in Chemistry from University of Florida and a Bachelor’s in Chemistry from Smith College.

Watch now

SPEAKERS

Chantelle Gaskin

Staff Scientist, Field Applications at Thermo Fisher Scientific

You might also like

Scalable chromatographic strategies for mRNA and saRNA purification from IVT

Tomas Kostelec

29 February

Watch

Precise mRNA purity assessment for accelerated therapeutic development and release testing

Paul Mania, Joe Ferraiolo

19 September

Watch

Quality by design in mRNA manufacturing: at-line monitoring coupled with DOE for higher IVT yield and efficiency of purification

Rok Sekirnik

3 December

in 11

Days

Register

Process in the product: a new analytical tool for AAV production optimization and monitoring

Blaž Bakalar, Ivana Petrović Koshmak

19 November

Watch